Agenus and Zydus Cadila announced on August 11, 2025, that they are collaborating on immunotherapy using botensilimab (BOT) and balstilimab (BAL).
2 reports, 1 independent
Updated Aug 11
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Agenus and Zydus Cadila announced on August 11, 2025, that they are collaborating on immunotherapy using botensilimab (BOT) and balstilimab (BAL).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Agenus
biotechnology company
Nothing else this week.
-
Zydus Cadila
Indian pharmaceutical stock company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireAgenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical
- Business WireAgenus to Provide Corporate Update and Second Quarter 2025 Financial Report LEXINGTON, Mass., July 31, 2025--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today